Acute Hepatitis Caused by Empagliflozin in a Nonalcoholic Fatty Liver Disease Patient

Abstract

Get full access to this article

View all access options for this article.

References

Naranjo

Busto

Sellers

et al . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.

Miljkovic

Dobric

Dragojevic-Simic

Consistency between causality assessments obtained with two scales and their agreement with clinical judgments in hepatotoxicity. Pharmacoepidemiol Drug Saf. 2011;20:272-285.

Jardiance (empagliflozin). Medical review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204629Orig1s000MedR.pdf). Accessed August 14, 2017.

Levine

Ann Lo

Wallia

Rogers

VanWagner

LB.

Dapagliflozin-induced acute-on-chronic liver injury. ACG Case Rep J. 2016;3:e169.

Scheen

AJ.

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33-59.